Back to Agenda
Session 4: Panel Discussion: Impact of Company Size on Labeling Innovation
Session Chair(s)
Hayley Parker, PhD, MSc
Vice President Regulatory Affairs
PepGen, United States
Lauren Brunke, PharmD, RPh
Senior Director, Global Regulatory Affairs, Global Labeling
Eli Lilly and Company, United States
Pharmaceutical and biotech companies can have unique approaches to how they conduct research, development, and commercialization. How about labeling? This session will explore how company size and labeling organizational structure can impact current business needs and future innovation. It will include a panel of representatives from different companies sharing their perspectives on the following areas: (1) mergers, acquisitions, and co-development with external companies; (2) roles, responsibilities, and processes; and (3) technology.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the role of the labeling function during mergers, acquisitions, and co-development with external companies
- Explain the impact that company size can have on an organization’s labeling processes and governance
- Discuss the impact that company size can have on labeling strategy and emerging technologies
Speaker(s)
Speaker
Ken Zerfass
Eli Lilly, United States
Director of Global Packaging and Labeling Artwork Development
Speaker
Nancy Cauwenberghs, PhD
J&J Innovative Medicines, Belgium
Head Global Labeling, GRA
Speaker
Deborah Bebbington
Bayer Plc, United Kingdom
Head Global Labeling
Have an account?